Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology

Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV)-specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well suited for comprehensive antigen selection, they are not applicable...

Full description

Saved in:
Bibliographic Details
Main Authors: Simon, Julia (Author) , Liu, Zhiwei (Author) , Brenner, Nicole (Author) , Yu, Kelly J. (Author) , Hsu, Wan-Lun (Author) , Wang, Cheng-Ping (Author) , Chien, Yin-Chu (Author) , Coghill, Anna E. (Author) , Chen, Chien-Jen (Author) , Butt, Julia (Author) , Proietti, Carla (Author) , Doolan, Denise L. (Author) , Hildesheim, Allan (Author) , Waterboer, Tim (Author)
Format: Article (Journal)
Language:English
Published: 23 April 2020
In: Journal of clinical microbiology
Year: 2020, Volume: 58, Issue: 5
ISSN:1098-660X
DOI:10.1128/JCM.00077-20
Online Access:Verlag, lizenzpflichtig, Volltext: https://dx.doi.org/10.1128/JCM.00077-20
Verlag, lizenzpflichtig, Volltext: https://jcm.asm.org/content/58/5/e00077-20
Get full text
Author Notes:Julia Simon, Zhiwei Liu, Nicole Brenner, Kelly J. Yu, Wan-Lun Hsu, Cheng-Ping Wang, Yin-Chu Chien, Anna E. Coghill, Chien-Jen Chen, Julia Butt, Carla Proietti, Denise L. Doolan, Allan Hildesheim, Tim Waterboer

MARC

LEADER 00000caa a2200000 c 4500
001 1734495219
003 DE-627
005 20220818214327.0
007 cr uuu---uuuuu
008 201002s2020 xx |||||o 00| ||eng c
024 7 |a 10.1128/JCM.00077-20  |2 doi 
035 |a (DE-627)1734495219 
035 |a (DE-599)KXP1734495219 
035 |a (OCoLC)1341368304 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Simon, Julia  |d 1993-  |e VerfasserIn  |0 (DE-588)1218797665  |0 (DE-627)1734496495  |4 aut 
245 1 0 |a Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology  |c Julia Simon, Zhiwei Liu, Nicole Brenner, Kelly J. Yu, Wan-Lun Hsu, Cheng-Ping Wang, Yin-Chu Chien, Anna E. Coghill, Chien-Jen Chen, Julia Butt, Carla Proietti, Denise L. Doolan, Allan Hildesheim, Tim Waterboer 
264 1 |c 23 April 2020 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.10.2020 
520 |a Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV)-specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well suited for comprehensive antigen selection, they are not applicable for large-scale studies. We adapted a 13-marker EBV antigen signature for NPC risk identified by proteome arrays to multiplex serology to establish an assay for large-scale studies. Taiwanese NPC cases (n = 175) and matched controls (n = 175) were used for assay validation. Spearman’s correlation was calculated, and the diagnostic value of all multiplex markers was assessed independently using the area under the receiver operating characteristic curve (AUC). Two refined signatures were identified using stepwise logistic regression and internally validated with 10-fold cross validation. Array and multiplex serology showed strong correlation for each individual EBV marker, as well as for a 13-marker combined model on continuous data. Two refined signatures with either four (LF2 and BGLF2 IgG, LF2 and BMRF1 IgA) or two (LF2 and BGLF2 IgG) antibodies on dichotomous data were identified as the most parsimonious set of serological markers able to distinguish NPC cases from controls with AUCs of 0.992 (95% confidence interval [CI], 0.983 to 1.000) and 0.984 (95% CI, 0.971 to 0.997), respectively. Neither differed significantly from the 13-marker model (AUC, 0.992; 95% CI, 0.982 to 1.000). All models were internally validated. Multiplex serology successfully validated the original EBV proteome microarray data. Two refined signatures of four and two antibodies were capable of detecting NPC with 99.2% and 98.4% accuracy. 
700 1 |a Liu, Zhiwei  |e VerfasserIn  |4 aut 
700 1 |a Brenner, Nicole  |e VerfasserIn  |0 (DE-588)118682039X  |0 (DE-627)1666090174  |4 aut 
700 1 |a Yu, Kelly J.  |e VerfasserIn  |4 aut 
700 1 |a Hsu, Wan-Lun  |e VerfasserIn  |4 aut 
700 1 |a Wang, Cheng-Ping  |e VerfasserIn  |4 aut 
700 1 |a Chien, Yin-Chu  |e VerfasserIn  |4 aut 
700 1 |a Coghill, Anna E.  |e VerfasserIn  |4 aut 
700 1 |a Chen, Chien-Jen  |e VerfasserIn  |4 aut 
700 1 |a Butt, Julia  |e VerfasserIn  |0 (DE-588)1135595070  |0 (DE-627)890510121  |0 (DE-576)489840442  |4 aut 
700 1 |a Proietti, Carla  |e VerfasserIn  |4 aut 
700 1 |a Doolan, Denise L.  |e VerfasserIn  |4 aut 
700 1 |a Hildesheim, Allan  |e VerfasserIn  |4 aut 
700 1 |a Waterboer, Tim  |e VerfasserIn  |0 (DE-588)119305494X  |0 (DE-627)1671578821  |4 aut 
773 0 8 |i Enthalten in  |t Journal of clinical microbiology  |d Washington, DC : Soc., 1975  |g 58(2020,5) Artikel-Nummer e00077-20, 9 Seiten  |h Online-Ressource  |w (DE-627)306587963  |w (DE-600)1498353-9  |w (DE-576)095092048  |x 1098-660X  |7 nnas  |a Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology 
773 1 8 |g volume:58  |g year:2020  |g number:5  |g extent:9  |a Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology 
856 4 0 |u https://dx.doi.org/10.1128/JCM.00077-20  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://jcm.asm.org/content/58/5/e00077-20  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20201002 
993 |a Article 
994 |a 2020 
998 |g 119305494X  |a Waterboer, Tim  |m 119305494X:Waterboer, Tim  |d 140000  |e 140000PW119305494X  |k 0/140000/  |p 14  |y j 
998 |g 1135595070  |a Butt, Julia  |m 1135595070:Butt, Julia  |p 10 
998 |g 118682039X  |a Brenner, Nicole  |m 118682039X:Brenner, Nicole  |p 3 
999 |a KXP-PPN1734495219  |e 3765047392 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"name":{"displayForm":["American Society for Microbiology"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"306587963","origin":[{"publisherPlace":"Washington, DC","dateIssuedDisp":"1975-","publisher":"Soc.","dateIssuedKey":"1975"}],"disp":"Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serologyJournal of clinical microbiology","id":{"issn":["1098-660X"],"zdb":["1498353-9"],"eki":["306587963"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 08.06.2021","Fortsetzung der Druck-Ausgabe"],"corporate":[{"display":"American Society for Microbiology","role":"isb"}],"title":[{"title":"Journal of clinical microbiology","title_sort":"Journal of clinical microbiology"}],"language":["eng"],"part":{"extent":"9","volume":"58","issue":"5","year":"2020","text":"58(2020,5) Artikel-Nummer e00077-20, 9 Seiten"},"pubHistory":["1.1975 -"]}],"note":["Gesehen am 02.10.2020"],"id":{"eki":["1734495219"],"doi":["10.1128/JCM.00077-20"]},"physDesc":[{"extent":"9 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1734495219","origin":[{"dateIssuedDisp":"23 April 2020","dateIssuedKey":"2020"}],"person":[{"display":"Simon, Julia","role":"aut","given":"Julia","family":"Simon"},{"family":"Liu","role":"aut","given":"Zhiwei","display":"Liu, Zhiwei"},{"given":"Nicole","role":"aut","display":"Brenner, Nicole","family":"Brenner"},{"given":"Kelly J.","role":"aut","display":"Yu, Kelly J.","family":"Yu"},{"family":"Hsu","given":"Wan-Lun","role":"aut","display":"Hsu, Wan-Lun"},{"family":"Wang","given":"Cheng-Ping","role":"aut","display":"Wang, Cheng-Ping"},{"given":"Yin-Chu","role":"aut","display":"Chien, Yin-Chu","family":"Chien"},{"family":"Coghill","given":"Anna E.","role":"aut","display":"Coghill, Anna E."},{"role":"aut","given":"Chien-Jen","display":"Chen, Chien-Jen","family":"Chen"},{"family":"Butt","display":"Butt, Julia","given":"Julia","role":"aut"},{"family":"Proietti","role":"aut","given":"Carla","display":"Proietti, Carla"},{"family":"Doolan","given":"Denise L.","role":"aut","display":"Doolan, Denise L."},{"display":"Hildesheim, Allan","given":"Allan","role":"aut","family":"Hildesheim"},{"given":"Tim","role":"aut","display":"Waterboer, Tim","family":"Waterboer"}],"name":{"displayForm":["Julia Simon, Zhiwei Liu, Nicole Brenner, Kelly J. Yu, Wan-Lun Hsu, Cheng-Ping Wang, Yin-Chu Chien, Anna E. Coghill, Chien-Jen Chen, Julia Butt, Carla Proietti, Denise L. Doolan, Allan Hildesheim, Tim Waterboer"]},"language":["eng"],"title":[{"title":"Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology","title_sort":"Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology"}]} 
SRT |a SIMONJULIAVALIDATION2320